Summary
McKesson Corporation (MCK) filed an 8-K on April 30, 2018, announcing a change to its Board of Directors. The most significant event detailed is the election of Bradley E. Lerman as a new independent director, effective April 24, 2018. This appointment increased the size of the Board from eight to nine members. Mr. Lerman brings extensive legal and corporate governance experience, having held senior legal roles at Medtronic, Fannie Mae, and Pfizer, as well as experience as a former prosecutor and partner at law firms.
Key Highlights
- 1McKesson Corporation elected Bradley E. Lerman as a new independent director to its Board of Directors.
- 2The election of Mr. Lerman increased the size of the Board from eight to nine members.
- 3Mr. Lerman's term as director will expire at the Company's 2018 Annual Meeting of Stockholders.
- 4Mr. Lerman has a distinguished career, previously serving as Senior Vice President, General Counsel, and Corporate Secretary at Medtronic.
- 5He also held executive legal positions at Fannie Mae and Pfizer, and was a partner at major law firms.
- 6Mr. Lerman has been determined to be independent and meets NYSE and Company director independence requirements.
- 7Mr. Lerman will receive compensation in accordance with the Company's standard arrangement for non-employee directors, including a prorated grant of restricted stock units valued at $45,000.